Pingchuan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pingchuan Liu has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Shaoyi Jiang
Meinig School of Biomedical Engineering, Cornell University, Ithaca, USA
4 shared publications Meng Cui
Department of Materials Science and Engineering, Cornell University, Ithaca, USA
3 shared publicationsYufei Ma
Meinig School of Biomedical Engineering, Cornell University, Ithaca, USA
3 shared publicationsYuping Hu
Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, USA
3 shared publicationsChenjue Tang
Meinig School of Biomedical Engineering, Cornell University, Ithaca, USA
2 shared publicationsRuoxin Li
Meinig School of Biomedical Engineering, Cornell University, Ithaca, USA
2 shared publications
Latest Publications
- 12 August 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (33) , 35861-35874
Molecular Design of Chiral Naphthalenediimide-Based Cations for Chiral One-Dimensional Metal Halide Semiconductors with Strong Chiroptical Activity and Amplified Charge Transport Ability
Chiral organic–inorganic metal halide semiconductors (MHSs) have emerged as promising materials for chiroptoelectronics, spintronics and ferroelectrics. However, commonly used chiral cations with nonconductive aliphatic and aromatic structures exhibit large energy gaps between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) relative to those of the inorganic frameworks. This energy mismatch between the chiral spacer and the inorganic sublattice creates a barrier that hinders charge-carrier transport, leading to inefficient out-of-plane charge mobility and strong quantum confinement effects. To address this challenge, we design and synthesize chiral n-type naphthalenediimide (NDI)-based cations, (R)-2-(7-ethyl-1,3,6,8-tetraoxo-3,6,7,8-tetrahydrobenzo[lmn][3,8]phenanthrolin-2(1H)-yl)propan-1-aminium ((R)-NDIEPA+). We successfully tune the LUMO level of (R)-NDIEPA+ to align with that of the inorganic sublattice, and the resulting chiral one-dimensional (1D) (R-NDIEPA)PbI3 MHS demonstrates a type II band alignment that facilitates charge separation, as evidenced by quenched photoluminescence and transient absorption dynamics indicative of ultrafast charge transfer across the organic–inorganic interface. As a result, these materials demonstrate an approximately 7-fold enhancement in electron mobility compared to the chiral 1D MHS incorporating nonconductive aromatic cations. (R-NDIEPA)PbI3 also exhibits a strong circular dichroism (CD) signal, confirming effective chirality transfer from the organic cation to the inorganic framework. These findings underscore the importance of leveraging the electronic properties of chiral organic cations while preserving strong chiroptical activity, highlighting the potential of (R-NDIEPA)PbI3 for chiroptoelectronic applications such as circularly polarized light photodetectors and other spintronic devices.
- 12 August 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (33) , 35861-35874
Molecular Design of Chiral Naphthalenediimide-Based Cations for Chiral One-Dimensional Metal Halide Semiconductors with Strong Chiroptical Activity and Amplified Charge Transport Ability
Chiral organic–inorganic metal halide semiconductors (MHSs) have emerged as promising materials for chiroptoelectronics, spintronics and ferroelectrics. However, commonly used chiral cations with nonconductive aliphatic and aromatic structures exhibit large energy gaps between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) relative to those of the inorganic frameworks. This energy mismatch between the chiral spacer and the inorganic sublattice creates a barrier that hinders charge-carrier transport, leading to inefficient out-of-plane charge mobility and strong quantum confinement effects. To address this challenge, we design and synthesize chiral n-type naphthalenediimide (NDI)-based cations, (R)-2-(7-ethyl-1,3,6,8-tetraoxo-3,6,7,8-tetrahydrobenzo[lmn][3,8]phenanthrolin-2(1H)-yl)propan-1-aminium ((R)-NDIEPA+). We successfully tune the LUMO level of (R)-NDIEPA+ to align with that of the inorganic sublattice, and the resulting chiral one-dimensional (1D) (R-NDIEPA)PbI3 MHS demonstrates a type II band alignment that facilitates charge separation, as evidenced by quenched photoluminescence and transient absorption dynamics indicative of ultrafast charge transfer across the organic–inorganic interface. As a result, these materials demonstrate an approximately 7-fold enhancement in electron mobility compared to the chiral 1D MHS incorporating nonconductive aromatic cations. (R-NDIEPA)PbI3 also exhibits a strong circular dichroism (CD) signal, confirming effective chirality transfer from the organic cation to the inorganic framework. These findings underscore the importance of leveraging the electronic properties of chiral organic cations while preserving strong chiroptical activity, highlighting the potential of (R-NDIEPA)PbI3 for chiroptoelectronic applications such as circularly polarized light photodetectors and other spintronic devices.
- 18 December 2025
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-15
Low reactogenicity and high tumour antigen expression from mRNA-LNPs with membrane-destabilizing zwitterionic lipids
Two key challenges in translating messenger RNA-based lipid nanoparticle (mRNA-LNP) cancer vaccines to clinical use are limited mRNA expression and unavoidable inflammatory responses. Here we develop a membrane-destabilizing zwitterionic ionizable lipid that enhances mRNA expression by promoting endosomal escape while reducing inflammatory reactogenicity. This lipid features a pyridine-based carboxybetaine (PyCB) zwitterionic headgroup, biodegradable multitailed alkyl chains and a tertiary amine linker. The PyCB headgroup forms a zwitterionic PyCB–water complex that protonates to a positively charged state below pH 6.8. This allows for good biocompatibility at physiological pH and strong protonation in endosomes, enabling earlier and more efficient mRNA release when synergistic with the tertiary amine and the tail moiety. Incorporating membrane-destabilizing zwitterionic lipids into the LNP formulation used in a commercially available mRNA vaccine significantly boosts mRNA expression in antigen-presenting cells within lymph nodes, enhancing cytotoxic T cell activation. In addition, these membrane-destabilizing zwitterionic lipid-containing nanoparticles show reduced inflammation and neutrophil infiltration at the injection site due to their zwitterionic property. These lipids are also compatible with existing targeted nanoparticle formulations, further improving mRNA delivery.
- 18 December 2025
- Published by Springer Nature in Nature Biomedical Engineering
- p. 1-15
Low reactogenicity and high tumour antigen expression from mRNA-LNPs with membrane-destabilizing zwitterionic lipids
Two key challenges in translating messenger RNA-based lipid nanoparticle (mRNA-LNP) cancer vaccines to clinical use are limited mRNA expression and unavoidable inflammatory responses. Here we develop a membrane-destabilizing zwitterionic ionizable lipid that enhances mRNA expression by promoting endosomal escape while reducing inflammatory reactogenicity. This lipid features a pyridine-based carboxybetaine (PyCB) zwitterionic headgroup, biodegradable multitailed alkyl chains and a tertiary amine linker. The PyCB headgroup forms a zwitterionic PyCB–water complex that protonates to a positively charged state below pH 6.8. This allows for good biocompatibility at physiological pH and strong protonation in endosomes, enabling earlier and more efficient mRNA release when synergistic with the tertiary amine and the tail moiety. Incorporating membrane-destabilizing zwitterionic lipids into the LNP formulation used in a commercially available mRNA vaccine significantly boosts mRNA expression in antigen-presenting cells within lymph nodes, enhancing cytotoxic T cell activation. In addition, these membrane-destabilizing zwitterionic lipid-containing nanoparticles show reduced inflammation and neutrophil infiltration at the injection site due to their zwitterionic property. These lipids are also compatible with existing targeted nanoparticle formulations, further improving mRNA delivery.
- Open Access
- 10 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (41) , eady6460
Replacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation
The spleen is emerging as a key vaccination target. However, existing lipid nanoparticles (LNPs) primarily accumulate in the liver, limiting their efficacy in vaccine therapy. The cholesterol in current LNP formulations promotes their uptake by hepatocytes, while the polyethylene glycol-modified (PEGylated) lipids induce PEG immunogenicity, further reducing the efficacy in the setting of repeated administrations. We develop a three-component (ThrCo) LNP by replacing cholesterol and PEGylated lipids in Pfizer-BioNTech LNPs with zwitterionic pyridine carboxybetaine (PyCB) ionizable lipids (ILs), achieving ~70% lower liver accumulation and a 4.5-fold increase in spleen-specific mRNA translation. PyCB ILs enhance LNP hydrophilicity, stabilizing the outer membrane to compensate for cholesterol removal. PyCB groups also exhibit strong protonation at endosomal pH, facilitating mRNA translation. The zwitterionic surface of ThrCo LNP reduces protein adsorption, thereby preventing the accelerated blood clearance effect caused by PEGylated lipids following repeated administrations. Thus, ThrCo LNP–based vaccines efficiently deliver mRNA to splenic antigen-presenting cells, boosting immune responses and improving therapeutic outcomes.
- 10 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (41) , eady6460
Open AccessReplacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation
The spleen is emerging as a key vaccination target. However, existing lipid nanoparticles (LNPs) primarily accumulate in the liver, limiting their efficacy in vaccine therapy. The cholesterol in current LNP formulations promotes their uptake by hepatocytes, while the polyethylene glycol-modified (PEGylated) lipids induce PEG immunogenicity, further reducing the efficacy in the setting of repeated administrations. We develop a three-component (ThrCo) LNP by replacing cholesterol and PEGylated lipids in Pfizer-BioNTech LNPs with zwitterionic pyridine carboxybetaine (PyCB) ionizable lipids (ILs), achieving ~70% lower liver accumulation and a 4.5-fold increase in spleen-specific mRNA translation. PyCB ILs enhance LNP hydrophilicity, stabilizing the outer membrane to compensate for cholesterol removal. PyCB groups also exhibit strong protonation at endosomal pH, facilitating mRNA translation. The zwitterionic surface of ThrCo LNP reduces protein adsorption, thereby preventing the accelerated blood clearance effect caused by PEGylated lipids following repeated administrations. Thus, ThrCo LNP–based vaccines efficiently deliver mRNA to splenic antigen-presenting cells, boosting immune responses and improving therapeutic outcomes.
- Top Cited Papers
- 29 May 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (11) , 1852-1861
Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity
Messenger RNA (mRNA) therapeutics are a promising strategy to combat diverse diseases. Traditional lipid nanoparticle (LNP) formulations for mRNA delivery contain poly(ethylene) glycol (PEG), a polymer widely used in drug delivery carriers but that recently has been associated with efficacy and immunogenicity concerns. Here we report poly(carboxybetaine) (PCB) lipids as surrogates for PEG-lipids used in mRNA formulations. In vitro studies with immortalized and primary cells show that PCB-containing LNPs have higher mRNA transfection efficiency than PEG-containing LNPs across different formulations. Moreover, primary cell engineering and in vivo immunization studies in mice further demonstrate greater therapeutic efficacy of PCB-containing LNPs over their PEG counterparts. Mechanistic assays show that this improvement is attributed to enhanced endosomal escape of PCB-containing LNPs. These formulations exhibit a safe immunotoxicity profile and effectively mitigate the accelerated blood clearance effect that has been observed for PEG-containing LNPs, enabling repeated administrations without efficacy loss. Overall, these findings highlight PCB-containing LNPs as a potent and safe mRNA delivery platform for clinical applications.
- 29 May 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (11) , 1852-1861
Top Cited PapersPoly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity
Messenger RNA (mRNA) therapeutics are a promising strategy to combat diverse diseases. Traditional lipid nanoparticle (LNP) formulations for mRNA delivery contain poly(ethylene) glycol (PEG), a polymer widely used in drug delivery carriers but that recently has been associated with efficacy and immunogenicity concerns. Here we report poly(carboxybetaine) (PCB) lipids as surrogates for PEG-lipids used in mRNA formulations. In vitro studies with immortalized and primary cells show that PCB-containing LNPs have higher mRNA transfection efficiency than PEG-containing LNPs across different formulations. Moreover, primary cell engineering and in vivo immunization studies in mice further demonstrate greater therapeutic efficacy of PCB-containing LNPs over their PEG counterparts. Mechanistic assays show that this improvement is attributed to enhanced endosomal escape of PCB-containing LNPs. These formulations exhibit a safe immunotoxicity profile and effectively mitigate the accelerated blood clearance effect that has been observed for PEG-containing LNPs, enabling repeated administrations without efficacy loss. Overall, these findings highlight PCB-containing LNPs as a potent and safe mRNA delivery platform for clinical applications.